[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Ito J, Sekiya M, Miura K, Yoshimi K, Suzuki T, Seyama K, Izumi H, Uekusa T, Takahashi K: Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone. Intern Med; 2009;48(12):1061-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone.
  • The patient was 54-year-old woman diagnosed as recurrent invasive thymoma (type B3; WHO classification).
  • The combination of octreotide and prednisolone should be considered as one of the choices of treatment in patients with recurrent thymoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Octreotide / therapeutic use. Prednisolone / therapeutic use. Somatostatin / analogs & derivatives. Thymoma / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525599.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 51110-01-1 / Somatostatin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q20Q21Q62J / Cisplatin; RWM8CCW8GP / Octreotide; CISCA protocol
  •  go-up   go-down


2. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Nakata T, Sunamori M, Handa M, Kondo T, Sasano H: Estrogen inhibits cell proliferation through in situ production in human thymoma. Clin Cancer Res; 2005 Sep 15;11(18):6495-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen inhibits cell proliferation through in situ production in human thymoma.
  • PURPOSE: We showed previously estrogen receptor (ER) alpha as an independent prognostic marker in human thymoma.
  • EXPERIMENTAL DESIGN: We examined estrogen production using primary cultures of human thymoma epithelial cells (TEC), intratumoral estradiol (E(2)) concentrations, and status of these enzymes above using immunohistochemistry or semiquantitative reverse transcription-PCR.
  • Intratumoral E(2) concentrations were inversely correlated with EST, positively correlated with STS or 17beta-HSD type 1, and significantly higher in lower-grade or early-stage thymoma.
  • STS and/or 17beta-HSD type 1 status was inversely correlated with Ki-67 labeling index and associated with lower histologic grade or early clinical stages.
  • CONCLUSIONS: E(2) inhibits proliferation of TEC through ERalpha, which suggests that E(2) may be effective in treatment of thymoma, especially inoperable tumor, possibly through suppressing its cell proliferation activity.
  • EST status is a potent prognostic factor in thymoma through inactivating estrogens.
  • In situ estrogen synthesis through intracrine mechanism therefore may play important roles in tumorigenesis and/or development of thymoma through regulation of cell proliferation in an intracrine manner.
  • [MeSH-major] Cell Proliferation / drug effects. Estrogens / pharmacology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] 17-Hydroxysteroid Dehydrogenases / genetics. 17-Hydroxysteroid Dehydrogenases / metabolism. Adult. Aged. Aromatase / genetics. Aromatase / metabolism. Dose-Response Relationship, Drug. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Estradiol / biosynthesis. Estrogen Receptor alpha / metabolism. Estrone / biosynthesis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Progesterone / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Steryl-Sulfatase / genetics. Steryl-Sulfatase / metabolism. Sulfotransferases / genetics. Sulfotransferases / metabolism. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166425.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / progesterone receptor B; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol; EC 1.1.- / 17-Hydroxysteroid Dehydrogenases; EC 1.14.14.1 / Aromatase; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.4 / estrone sulfotransferase; EC 3.1.6.2 / Steryl-Sulfatase
  •  go-up   go-down


Advertisement
3. Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, Lane HY: Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. J Psychopharmacol; 2009 Nov;23(8):937-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V-akt murine thymoma viral oncogene homolog 1 (AKT1) is a serine/threonine kinase known as protein kinase B.
  • This study aims to examine the association of AKT1 polymorphisms with drug-free and post-treatment symptomatology and social function in patients with schizophrenia.
  • One hundred and twenty newly hospitalised patients with acutely exacerbated schizophrenia who had never been treated by atypical antipsychotics were recruited.
  • At drug-free status and after best possible treatment of risperidone, genotypes of each SNP did not influence performances in NOSIE, PANSS-total, -positive, -negative and -general psychopathology profiles.
  • [MeSH-major] Polymorphism, Single Nucleotide. Proto-Oncogene Proteins c-akt / genetics. Schizophrenia / genetics






Advertisement